Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 56,197	$ 45,804	$ 33,266
Cost of products sold	17,446	15,387	7,439
Selling, general and administrative	12,349	11,299	6,942
Research and development	7,084	6,557	6,407
Acquired in-process research and development	962	1,198	385
Other operating expense (income), net	432	0	(890)
Total operating costs and expenses	38,273	34,441	20,283
Operating earnings	17,924	11,363	12,983
Interest expense, net	2,384	2,280	1,509
Net foreign exchange loss	51	71	42
Other expense, net	2,500	5,614	3,006
Earnings before income tax expense	12,989	3,398	8,426
Income tax expense (benefit)	1,440	(1,224)	544
Net earnings	11,549	4,622	7,882
Net earnings attributable to noncontrolling interest	7	6	0
Net earnings attributable to AbbVie Inc.	$ 11,542	$ 4,616	$ 7,882
Per share data
Basic earnings per share (in dollars per share)	$ 6.48	$ 2.73	$ 5.30
Diluted earnings per share (in dollars per share)	$ 6.45	$ 2.72	$ 5.28
Weighted-average basic shares outstanding (in shares)	1,770	1,667	1,481
Weighted-average diluted shares outstanding (in shares)	1,777	1,673	1,484